N
LENZ

Nuveen’s LENZ Therapeutics LENZ Stock Holding History

Nuveen’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$368K Buy
40,190
+285
+0.7% +$4K ﹤0.01% 2951
2025
Q4 		$638K Sell
39,905
-245,638
-86% -$7.16M ﹤0.01% 2783
2025
Q3 		$13.3M Buy
285,543
+107,329
+60% +$3.95M ﹤0.01% 1391
2025
Q2 		$5.22M Buy
178,214
+111,177
+166% +$3.02M ﹤0.01% 1850
2025
Q1 		$1.72M Buy
67,037
+43,907
+190% +$1.08M ﹤0.01% 2391
2024
Q4 		$668K Hold
23,130
– – ﹤0.01% 2880
2024
Q3 		$549K Hold
23,130
– – ﹤0.01% 2984
2024
Q2 		$400K Buy
+23,130
New +$404K ﹤0.01% 3064
2024
Q1 		– Sell
-5,677
Closed -$104K – 3308
2023
Q4 		$104K Hold
5,677
– – ﹤0.01% 3283
2023
Q3 		$98.5K Hold
5,677
– – ﹤0.01% 3124
2023
Q2 		$103K Buy
+5,677
New +$113K ﹤0.01% 3162
2022
Q2 		– Sell
-7,744
Closed -$373K – 3514
2022
Q1 		$373K Buy
7,744
+4,380
+130% +$274K ﹤0.01% 3081
2021
Q4 		$240K Sell
3,364
-1,538
-31% -$127K ﹤0.01% 3213
2021
Q3 		$562K Buy
+4,902
New +$726K ﹤0.01% 3147

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Nuveen's LENZ Position: Q1 2026 in Review

Nuveen increased its LENZ Therapeutics (LENZ) stake by 0.71% in Q1 2026, buying an estimated $4K and bringing the position to 40,190 shares worth $368K. The position accounts for ﹤0.01% of the portfolio, ranked #2951.

Nuveen first reported a position in LENZ in Q3 2021 and has held it in 14 quarters since. The position peaked at $13.3M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Nuveen held 40,190 shares of LENZ Therapeutics worth $368K as of Q1 2026.
  • Nuveen bought 285 LENZ Therapeutics shares in Q1 2026, an estimated $4K.
  • LENZ Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2951 holding.
  • Nuveen first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 14 quarters since.
  • Nuveen's LENZ Therapeutics position peaked at $13.3M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.